Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03315988
Other study ID # 0625
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 4, 2017
Est. completion date January 7, 2019

Study information

Verified date September 2018
Source University of Leicester
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The amount of people with diabetes mellitus has now reached over 4 million in the United Kingdom. Type 2 diabetes accounts for the majority of all cases of diabetes and increases the risk of many other diseases such as heart problems. Plant based diets are thought to be an effective way to improve markers of health related to type 2 diabetes and heart disease. One way that a plant based diet improves health could be through reducing waste products that are generated in the gut by the bacteria that break down food as part of the digestion process. For example, the digestion of some meats, fish and eggs results in the creation of a substance called Trimethylamine-N-Oxide (TMAO) which has been linked to worse health outcomes in several studies. However, the full impact on TMAO and blood glucose levels of swapping regular meat consumption for a plant based vegan diet is not fully understood and requires further research. Therefore, the aim of this study will be to develop and undertake a clinical trial to investigate the effects of an 8-week vegan diet on TMAO levels and post challenge glucose levels in individuals with dysglycaemia (drug naïve).

The study will be interventional single group prospective trial of adults aged 18-75 years of age from a multi-ethnic population with dysglycaemia (drug naïve). A sample of 29 people will be sought. The dietary intervention (vegan diet) will last 8 weeks. Then, the participants will go back to their normal diet and come for their final visit after a four week follow-up period (week 12). To assess the effectiveness of the intervention, primary and secondary outcome data collected at baseline will be compared with data collected at 1 week, 8 weeks and 12 weeks.


Description:

Study Design

Interventional single group prospective trial in a patient population with identified dysglycaemia within the past 36 months defined as 2h post-challenge glucose ≥7.8 mmol/L after a standard oral glucose tolerance test or HbA1c ≥5.7% (39-46 mmol/mol). This phase clinical trial will evaluate the efficacy and underlining mechanisms of a vegan diet in promoting cardiometabolic health in those with dysglycaemia. Specifically, this trial will aim to investigate the effect of an 8-week vegan diet with follow-up at 1, 8 and 12 weeks.

Study Setting

The study will be co-ordinated within the Leicester Biomedical Research Centre (Leicester Diabetes Centre) at the Leicester General Hospital. Clinical measurement sessions will be carried out by the appointed research team. Participants will be asked to visit the study centre on five occasions.

Intervention Description and Definition

The participants will be asked to follow a diet that excludes foods hypothesised to support the syntheses of TMAO, particularly meat (any), eggs and fish (any). A number of studies suggest that dairy products may also have an effect in modulating TMAO production whereas other studies do not. Therefore, in order to avoid any potential contaminating or confounding effect, dairy products will also be avoided.

The diet employed in this study is broadly aligned to a vegan diet. The term vegan will be used to aid behaviour change and food choice. For example, an increasing array of products are now pack marked as vegan. The participants will be asked to keep their diet similar to their original and the Registered Dietitian involved in this study will plan their weekly menus accordingly.


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date January 7, 2019
Est. primary completion date January 7, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Participant is willing and able to give informed consent for participation in the study

- And either:

- Overweight (White: BMI>25 - <30, South Asian/ Black and minority ethnic group <27.5) with HbA1c between HbA1c =5.7% and = 8% (39-64 mmol/mol) identified within the last 36 months

- Obese: (White: BMI =30, South Asian/ Black and minority ethnic group: =27.5)

- Male or Female

- Aged 18 - 75 years inclusive

- Able to understand, read and speak the English language to a sufficient level to understand and take part to the study in the investigators opinion

- Have access to a phone, and willing to use it as part of the study

- Regular meat and/or fish eater (at least 3 times per week)-self reported

Exclusion Criteria:

Participant is unwilling or unable to give informed consent

- Non-English speakers

- HbA1c above 8% (64 mmol/mol)

- Taking any form of glucose lowering medication currently or within the last 60 days

- Current smokers

- Current use of vegan or vegetarian diet

- Recent significant weight change (10% or more) over the last 3 months

- Pregnancy/lactation

- Clinical eating disorder as detected by their GP or relevant health professional (e.g. dietitian)

- Have a terminal illness

- Current or recent (within 6 months) oral antibiotics or steroid use as their usage could impact on the gut bacteria profile

- Ongoing CVD (e.g. angina) *

- In the circumstance that an individual is not sure whether they meet the inclusion/ exclusion criteria, (i.e. they are not sure if they have ongoing CVD) this will be reviewed by a named medic on the delegation of authority log for a clinical decision to be made during baseline.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Adoption of a vegan diet
Adoption of a vegan diet The participants of this study wil be asked to adopt a vegan diet under the supervision of a Registered Dietitian.

Locations

Country Name City State
United Kingdom Leicester Diabetes Centre Leicester

Sponsors (2)

Lead Sponsor Collaborator
University of Leicester University Hospitals, Leicester

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline TMAO plasma levels at 1, 8 and 12 weeks. urine and plasma samples for TMAO (µM) at 1 (+ 5 days) week , 8 (+/- 5 days) weeks and 12 weeks (+/- 5 days)
Primary Change from Baseline 3-hour post-challenge glucose levels at 1, 8 and 12 weeks. blood samples (mmol/l) at 1 (+ 5 days) week , 8 (+/- 5 days) weeks and 12 weeks (+/- 5 days)
Secondary TMAO (µM) urine levels at baseline. urine samples at baseline
Secondary Change from Baseline in TMAO urine/plasma levels at 1 week following a vegan diet. urine and plasma samples; TMAO (µM) at 1 week (+ 5 days)
Secondary Change from Baseline 3-hour post-challenge glucose levels at 1 week following a vegan diet. blood samples for glucose (mmol/l) at 1 week (+ 5 days)
Secondary Change from week 8 in TMAO urine/plasma levels at 4 weeks after diet has returned to normal (week 12). urine and plasma samples for TMAO (µM) at 12 weeks (+/- 5 days)
Secondary Change from week 8 in 3-hour post-challenge glucose levels at 4 weeks after diet has returned to normal (week 12). blood samples for glucose (mmol/l) at 12 weeks (+/- 5 days)
Secondary Change from Baseline in body composition using dual energy X-ray absorptiometry (DXA) scan at 8 weeks following a vegan diet. DXA Scan at baseline and week 8 (+/- 5 days)
Secondary Change from Baseline in biochemical measures of cardiometabolic health including post-challenge insulin at 1 week. blood samples (mmol/l) 1 week (+5 days)
Secondary Change from Baseline in biochemical measures of cardiometabolic health including post-challenge insulin at 8 weeks. blood samples (mmol/l) 8 weeks (+/- 5 days)
Secondary Change from Baseline in biochemical measures of cardiometabolic health including post-challenge insulin at 12 weeks. blood samples (mmol/l) 12 weeks (+/- 5 days)
Secondary Change from Baseline in biochemical measures of cardiometabolic health including fasting lipids and at 1 week. blood samples (mmol/l) 1 week (+5 days)
Secondary Change from Baseline in biochemical measures of cardiometabolic health including fasting lipids and inflammatory markers at 8 weeks. blood samples (mmol/l) 8 weeks (+/- 5 days)
Secondary Change from Baseline in biochemical measures of cardiometabolic health including fasting lipids at 12 weeks. blood samples (mmol/l) 12 weeks (+/- 5 days)
Secondary Change from Baseline in biochemical measures of cardiometabolic health including inflammatory markers at 1 week. blood samples (mmol/l) 1 week (+5 days)
Secondary Change from Baseline in biochemical measures of cardiometabolic health including inflammatory markers at 8 weeks. blood samples (mmol/l) 8 weeks (+/- 5 days)
Secondary Change from Baseline in biochemical measures of cardiometabolic health including inflammatory markers at 12 weeks. blood samples (mmol/l) 12 weeks (+/- 5 days)
Secondary The extent to which changes in the primary outcomes are mediated by, or independent of, changes to body composition. DXA scan baseline
Secondary The extent to which changes in the primary outcomes are mediated by, or independent of, changes to body composition. DXA scan week 8 (+/- 5 days)
Secondary The extent to which changes in the primary outcomes are mediated by, or independent of, changes to lifestyle factors. 3-day diet diaries baseline
Secondary The extent to which changes in the primary outcomes are mediated by, or independent of, changes to lifestyle factors. 3-day diet diaries counselling visit (+5 days)
Secondary The extent to which changes in the primary outcomes are mediated by, or independent of, changes to lifestyle factors. 3-day diet diaries week 1 (+5 days)
Secondary The extent to which changes in the primary outcomes are mediated by, or independent of, changes to lifestyle factors. 3-day diet diaries week 8 (+/- 5 days)
Secondary The extent to which changes in the primary outcomes are mediated by, or independent of, changes to lifestyle factors. 3-day diet diaries week 12 (+/- 5 days)
Secondary The extent to which changes in the primary outcomes are mediated by, or independent of, changes to lifestyle factors. accelerometers weeks 1-12
Secondary Semi-structured interviews with the completers, at the end of the study, to investigate perception responses having been on a vegan diet. semi-structured interviews at week 12 (+/- 5 days)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2